Analyst sees positive future for Merck KGaA in MS market, as FDA accepts Mavenclad for review

The US Food and Drug Administration’s acceptance of Merck KGaA’s (MRK: DE) resubmitted application for Mavenclad (cladribine), seven years after the original application,  is seen as a positive in terms of the German drugmakers future in the multiple sclerosis therapy sector.